WO2011071725A1 - Composés hétérocycliques contenant un cœur pyrrolopyridine ou benzimidazole - Google Patents

Composés hétérocycliques contenant un cœur pyrrolopyridine ou benzimidazole Download PDF

Info

Publication number
WO2011071725A1
WO2011071725A1 PCT/US2010/058482 US2010058482W WO2011071725A1 WO 2011071725 A1 WO2011071725 A1 WO 2011071725A1 US 2010058482 W US2010058482 W US 2010058482W WO 2011071725 A1 WO2011071725 A1 WO 2011071725A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
oxo
pyrrolo
carboxamide
tetrahydro
Prior art date
Application number
PCT/US2010/058482
Other languages
English (en)
Inventor
Stephen James Boyer
Jennifer Burke
Xin Guo
Thomas Martin Kirrane Jr.
Roger John Snow
Yunlong Zhang
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Priority to EP10788192.2A priority Critical patent/EP2509979B1/fr
Priority to JP2012543150A priority patent/JP5643332B2/ja
Priority to US13/513,973 priority patent/US9073926B2/en
Publication of WO2011071725A1 publication Critical patent/WO2011071725A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Definitions

  • the present invention relates to novel compounds which inhibit RSK, methods of making such compounds and their use as medicaments.
  • the p90 ribosomal s6 kinases are a group of serine/threonine kinases that are constituents of the AGC subfamily in the human kinome.
  • RSKs ribosomal s6 kinases
  • Each of the 4 RSK isoforms are products of separate genes and are characterized by 75% - 80% sequence identity. While the RSK isoforms are widely distributed among human tissues, their variable tissue expression patterns indicate that they may have distinct physiologic/pathologic roles.
  • the RSK isoforms are activated by growth factors, cytokines, peptide hormones and neurotransmitters that stimulate the Ras-ERK pathway.
  • NHE1 Na + /H + exchanger isoform 1
  • RSK-mediated phosphorylation of NHE1 at S703 is responsible for increased NHE1 activity following Ang II stimulation, oxidative stress, and myocardial injury.
  • NHE1 is a highly validated target for its role in both ischemia reperfusion (I/R) injury and congestive heart failure.
  • Increased NHE1 activity correlates to the extent of myocardial damage following I/R, while NHE1 inhibitors administered in a prophylactic manner are capable of preserving cardiac function after I/R.
  • NHE1 activity is observed in isolated myocytes from failing human hearts and in animal models of hypertrophy suggesting chronic activation of this exchanger in cardiovascular pathologies.
  • Adverse events such as headache, eye pain, and paresthesia, were reported in clinical trials, and it is hypothesized that these events are due to direct and complete NHE1 inhibition which impairs its physiological function of maintaining intracellular pH.
  • alternate approaches that do not inhibit basal NHE1 activity but regulate activity during periods of cardiovascular stress may offer an additional safety margin.
  • RSK has been recognized as a predominant kinase that phosphorylates the c-terminal regulatory region of NHE1 and is required for NHE1 activation in response to I/R, oxidative stress, and receptor activation by Ang II and phenylephrine.
  • Recent studies by Maekawa et al. (Naoya Maekawa, Jun-ichi Abe, Tetsuro Shishido, Seigo Itoh, Bo Ding, Virendra K. Sharma, Shey-Shing Sheu, Burns C. Blaxall and Bradford C. Berk Circulation 113:2516-2523, 2006) demonstrated that that RSK was rapidly activated in the heart tissue exposed to I/R.
  • the present invention provides novel compounds which inhibit RSK2 activity and are thus useful for treating a variety of diseases and disorders that are mediated through the activity of RSKs including allergic, pulmonary, fibrotic, inflammatory and cardiovascular diseases and cancer.
  • This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
  • X is N or C
  • Y is C or N
  • R 1 is aryl or heteroaryl; wherein each of the foregoing R 1 groups is optionally substituted with 1 to 3 substituents selected from R 6 ;
  • R 2" and R 3 J are each independently H or C - C 5 alkyl; or
  • R 2 and R 3 together with the carbon atom to which they are attached, form a C 3 - Cg cycloalkyl ring;
  • R 4 and R 5 are each independently H or C - C 5 alkyl; or
  • R 4 and R 5 together with the carbon atom to which they are attached, form a C 3 - Cg cycloalkyl ring; each R 6 is independently Ci - C 5 alkyl, -Ci - C 5 alkylamino, -Ci - C 5 alkyl-NH-Ci - C 3 alkyl, -Ci - C 5 alkyl-N(Ci - C 3 alkyl) 2 , -Ci - C 5 alkyl-aryl, -Ci - C 5 alkyl-heteroaryl, -Ci - C 5 alkyl-heterocyclyl, Ci - C 5 alkoxyl, C 3 - C 8 cycloalkyl, -C(0)NH 2, -C(0)NH-Ci - C 5 alkyl, -C(0)N(Ci - C 5 alky) 2 , -C(0)NH- C 3 - C 8 cycloalkyl, -C(0)OCi
  • Y is N
  • R 1 is aryl or heteroaryl; wherein each of the foregoing R 1 groups is optionally substituted with 1 to 3 substituents selected from R 6 ;
  • R 2" and R 3 J are each independently H or Ci - C 5 alkyl; or
  • R 2 and R 3 together with the carbon atom to which they are attached, form a C 3 - Cg cycloalkyl ring;
  • R 4 and R 5 are each independently H or Ci - C 5 alkyl; or
  • R 4 and R 5 together with the carbon atom to which they are attached, form a C 3 - Cg cycloalkyl ring; and each R 6 is independently Ci - C 5 alkyl, -Ci - C 5 alkylamino, -Ci - C 5 alkyl-NH-Ci - C 3 alkyl, -Q - C 5 alkyl-N(Ci - C 3 alkyl) 2 , -Q - C 5 alkyl-aryl, -Ci - C 5 alkyl-heteroaryl, -Ci - C 5 alkyl-heterocyclyl, Ci - C 5 alkoxyl, C 3 - C 8 cycloalkyl, -C(0)NH 2, -C(0)NH-Ci - C 5 alkyl, -C(0)N(Ci - C 5 alky) 2 , -C(0)NH- C 3 - C 8 cycloalkyl, -C(0)OCi
  • R 1 is phenyl, isoxazolyl, oxazolyl, imidazolyl, pyrazolyl, thiazolyl, furanyl, thienyl, pyrrolyl, pyridinyl, pyrimidinyl, pyridazinyl, benzimidazolyl, benzopyrazolyl, pyrazolopyridinyl, imidazopyridinyl, indolyl, or quinolinyl; wherein each of the foregoing R 1 groups is optionally substituted with 1 to 3 substituents selected from R 6 ;
  • R" and R J are each independently H or Ci - C 3 alkyl; or
  • R and R together with the carbon atom to which they are attached, form a C 3 - C 6 cycloalkyl ring;
  • R 4 and R 5 are each independently H or Ci - C 3 alkyl; or
  • R 4 and R 5 together with the carbon atom to which they are attached, form a C 3 - C 6 cycloalkyl ring; and each R 6 is independently Ci - C 5 alkyl, -Ci - C 5 alkylamino, -Ci - C 5 alkyl-NH-Ci - C 3 alkyl, -Ci - C 5 alkyl-N(Ci - C 3 alkyl) 2 , -Ci - C 5 alkyl-phenyl, Ci - C 3 alkoxyl, C 3 - C 6 cycloalkyl, -C(0)NH 2> -C(0)NH-Ci - C 3 alkyl, -C(0)N(Ci - C 3 alkyl) 2 , -C(0)NH- C 3 - C cycloalkyl, halogen, cyano, phenyl, isoxazolyl, oxazolyl, imidazolyl, pyrazolyl,
  • R 1 is phenyl, isoxazolyl, imidazolyl, pyrazolyl, pyridinyl, benzimidazolyl, pyrazolopyridinyl, imidazopyridinyl or quinolinyl; wherein each of the foregoing R 1 groups is optionally substituted with 1 to 3 substituents selected from R 6 ;
  • R 2" and R 3 J are each independently H or d - C 3 alkyl;
  • R 4 and R 5 are each independently H or C - C 3 alkyl;
  • each R 6 is independently Ci - C 5 alkyl, -Ci - C 5 alk l-N(Ci - C 2 alkyl) 2 , -CH 2 -phenyl, - C(0)NH 2, -C(0)NH- C 3 - C 6 cycloalkyl, halogen, phenyl imidazolyl or thiazolyl; wherein each heteroaryl of said R 6 is optionally independently
  • R 1 is benzimidazolyl substituted with 1 to 2 substituents selected from R 6 ;
  • R 2" and R 3 J are each independently H or methyl; R 4 and R 5 are H; and
  • R 6 is Ci - C 3 alkyl; or a pharmaceutically acceptable salt thereof.
  • X is N; Y is C; R 1 is aryl or heteroaryl, each optionally substituted with 1 to 3 substituents selected from
  • R" R J are each independently H or Ci - C 5 alkyl
  • R and R together with the carbon atom to which they are attached, form a C 3 - C 8 cycloalkyl ring;
  • R 4 and R 5 are each independently H or Ci - C 5 alkyl; or
  • R 4 and R 5 together with the carbon atom to which they are attached, form a C3 - Cg cycloalkyl ring; each R 6 is independently Ci - C 5 alkyl, -Ci - C 5 alkylamino, -Ci - C 5 alkyl-NH-Ci - C 3 alkyl, -Ci - C 5 alkyl-N(Ci - C 3 alkyl) 2 , -Ci - C 5 alkyl-aryl, -Ci - C 5 alkyl-heteroaryl, -Ci - C 5 alkyl-heterocyclyl, Ci - C 5 alkoxyl, C 3 - C 8 cycloalkyl, -C(0)NH 2, -C(0)NH-Ci - C 5 alkyl, -C(0)N(Ci - C 5 alky) 2 , -C(0)NH- C 3 - C 8 cycloalkyl, -C(0)OCi
  • R is phenyl, isoxazolyl, oxazolyl, imidazolyl, pyrazolyl, thiazolyl, furanyl, thienyl, pyrrolyl, pyridinyl, pyrimidinyl, pyridazinyl, benzimidazolyl, benzopyrazolyl, pyrazolopyridinyl, imidazopyridinyl or quinolinyl; wherein each of the foregoing R 1 groups is optionally substituted with 1 to 3 substituents selected from R 6 ;
  • R" a R J are each independently H or C - C 3 alkyl
  • R R together with the carbon atom to which they are attached, form a C 3 - C 6 cycloalkyl ring;
  • R 4 and R 5 are each independently H or Ci - C 3 alkyl; or
  • R 4 and R 5 together with the carbon atom to which they are attached, form a C 3 - C 6 cycloalkyl ring; and each R 6 is independently d - C 5 alkyl, -Q - C 5 alkylamino, -Ci - C 5 alkyl-NH-Ci - C 3 alkyl, -Q - C 5 alkyl-N(Ci - C 3 alkyl) 2 , -Ci - C 5 alkyl-phenyl, -Ci - C 5 alkyl-heteroaryl, - Ci - C 5 alkyl-tetrahydropyranyl, -Ci - C 5 alkyl-tetrahydrofuranyl, -Ci - C 5 alkyl- morpholinyl, Ci - C 5 alkoxyl, C 3 - C 8 cycloalkyl, -C(0)NH 2> -C(0)NH-Ci - C 5 alkyl,
  • R is phenyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, pyridinyl, benzimidazolyl, pyrazolopyridinyl or quinolinyl; wherein each of the foregoing Rl groups optionally substituted with 1 to 3 substituents selected from R 6 ;
  • R" and R J are each independently H or Ci - C 3 alkyl
  • R 4 and R 5 are each independently H or Ci - C 3 alkyl; and each R 6 is independently Ci - C 5 alkyl, -Ci - C 5 alk l-N(Ci - C 2 alkyl) 2 , -Ci - C 3 alkyl- phenyl, -Ci - C 3 alkyl-pyridinyl, , -Ci - C 3 alkyl-tetrahydrofuranyl, -Ci - C 3 alkyl- morpholinyl, C 3 - C 6 cycloalkyl, -C(0)NH 2> -C(0)NH-Ci - C 3 alkyl, -C(0)NH- C 3 - C cycloalkyl, -C(0)OCi - C 3 alkyl, halogen, tetrahydropyranyl, phenyl, imidazolyl or thiazolyl; wherein each heteroaryl group of said R 6 is optionally independently substituted
  • R 1 is phenyl, isoxazolyl, imidazolyl, pyrazolyl, pyridinyl, benzimidazolyl, pyrazolopyridinyl or quinolinyl; wherein each of the foregoing R 1 groups is optionally substituted with 1 to 3 substituents selected from R 6 ;
  • R" and R J are each independently H or methyl;
  • R 1 is phenyl, isoxazolyl, imidazolyl, pyrazolyl, pyridinyl, pyrazolopyridinyl or quinolinyl; wherein each of the foregoing R 1 groups is optionally substituted with 1 to 3 substituents selected from R 6 ; and each R 6 is independently Q - C 5 alkyl, -Q - C 3 alkyl-phenyl, -Q - C 3 alkyl-pyridinyl, , -Ci - C 3 alkyl-tetrahydrofuranyl, -Ci - C 3 alkyl-morpholinyl, -C(0)NH 2 , -C(0)NH- C 3 - C 6 cycloalkyl or tetrahydropyranyl; or a pharmaceutically acceptable salt thereof.
  • the invention relates to a compound selected from those identified as Examples 1 to 105 in Table 1 below, and any combination thereof, and pharmaceutically acceptable salts thereof.
  • the invention relates to a compound selected from consisting of:
  • the invention relates to a compound selected from the group consisting of:
  • the invention also relates to pharmaceutical preparations, containing as active substance one or more compounds of the invention, or the pharmaceutically acceptable derivatives thereof, optionally combined with conventional excipients and/or carriers.
  • Compounds of the invention also include their isotopically-labelled forms.
  • An isotopically-labelled form of an active agent of a combination of the present invention is identical to said active agent but for the fact that one or more atoms of said active agent have been replaced by an atom or atoms having an atomic mass or mass number different from the atomic mass or mass number of said atom which is usually found in nature.
  • isotopes which are readily available commercially and which can be incorporated into an active agent of a combination of the present invention in accordance with well established procedures, include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, e.g., 2 H, 3 H, 13 C, 14 C, 15 N, 18 0, 17 0, 31 P, 32 P, 35 S, 18 F, and 36 C1, respectively.
  • An active agent of a combination of the present invention, a prodrug thereof, or a pharmaceutically acceptable salt of either which contains one or more of the above-mentioned isotopes and/or other isotopes of other atoms is contemplated to be within the scope of the present invention.
  • the invention includes the use of any compounds of described above containing one or more asymmetric carbon atoms may occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. Isomers shall be defined as being enantiomers and diastereomers. All such isomeric forms of these compounds are expressly included in the present invention. Each stereogenic carbon may be in the R or S configuration, or a combination of configurations. Some of the compounds of the invention can exist in more than one tautomeric form. The invention includes methods using all such tautomers.
  • C 1-6 alkoxy is a C 1-6 alkyl with a terminal oxygen, such as methoxy, ethoxy, propoxy, butoxy.
  • All alkyl, alkenyl, and alkynyl groups shall be understood as being branched or unbranched where structurally possible and unless otherwise specified.
  • Other more specific definitions are as follows: The term “alkyl” refers to both branched and unbranched alkyl groups. It should be understood that any combination term using an "alk” or “alkyl” prefix refers to analogs according to the above definition of "alkyl”.
  • alkoxy alkyl groups linked to a second group via an oxygen or sulfur atom.
  • carbocycle or "cycloalkyl” refers to a nonaromatic 3 to 10-membered (but preferably, 3 to 6-membered) monocyclic carbocyclic radical or a nonaromatic 6 to 10- membered fused bicyclic, bridged bicyclic, or spirocyclic carbocyclic radical.
  • the C3.10 carbocycle may be either saturated or partially unsaturated, and the carbocycle may be attached by any atom of the cycle which results in the creation of a stable structure.
  • Non- limiting examples of 3 to 10-membered monocyclic carbocycles include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptanyl, cycloheptenyl, and cyclohexanone.
  • Non-limiting examples of 6 to 10-membered fused bicyclic carbocyclic radicals include bicyclo[3.3.0]octane, bicyclo[4.3.0]nonane, and bicyclo[4.4.0]decanyl (decahydronaphthalenyl).
  • Non-limiting examples of 6 to 10- membered bridged bicyclic carbocyclic radicals include bicyclo [2.2.2]heptanyl, bicyclo[2.2.2]octanyl, and bicyclo[3.2.1]octanyl.
  • Non-limiting examples of 6 to 10- membered spirocyclic carbocyclic radicals include but are not limited to spiro[3,3]heptanyl, spiro[3,4]octanyl and spiro[4,4]heptanyl.
  • aryl refers to aromatic hydrocarbon rings containing from six to ten carbon ring atoms.
  • C 6-1 o aryl includes monocyclic rings and bicyclic rings where at least one of the rings is aromatic.
  • Non-limiting examples of C 6 -io aryls include phenyl, indanyl, indenyl, benzocyclobutanyl, dihydronaphthyl, tetrahydronaphthyl, naphthyl, benzocycloheptanyl and benzocycloheptenyl.
  • heterocycle refers to a stable nonaromatic 4-8 membered monocyclic heterocyclic radical or a stable nonaromatic 6 to 11-membered fused bicyclic, bridged bicyclic or spirocyclic heterocyclic radical.
  • the 5 to 11-membered heterocycle consists of carbon atoms and one or more, preferably from one to four heteroatoms chosen from nitrogen, oxygen and sulfur.
  • the heterocycle may be either saturated or partially unsaturated.
  • Non-limiting examples of nonaromatic 4-8 membered monocyclic heterocyclic radicals include tetrahydrofuranyl, azetidinyl, pyrrolidinyl, pyranyl, tetrahydropyranyl, dioxanyl, thiomorpholinyl, l,l-dioxo-l 6 -thiomorpholinyl, morpholinyl, piperidinyl, piperazinyl, and azepinyl.
  • Non-limiting examples of nonaromatic 6 to 11-membered fused bicyclic radicals include octahydroindolyl, octahydrobenzofuranyl, and octahydrobenzothiophenyl.
  • Non-limiting examples of nonaromatic 6 to 11-membered bridged bicyclic radicals include 2- azabicyclo[2.2.1]heptanyl, 3-azabicyclo[3.1.0]hexanyl, and 3-azabicyclo[3.2.1]octanyl.
  • Non-limiting examples of nonaromatic 6 to 11-membered spirocyclic heterocyclic radicals include 7-aza-spiro[3,3]heptanyl, 7-spiro[3,4]octanyl, and 7-aza- spiro[3,4]octanyl.
  • heteroaryl shall be understood to mean an aromatic 5 to 6-membered monocyclic heteroaryl or an aromatic 7 to 11-membered heteroaryl bicyclic ring where at least one of the rings is aromatic, wherein the heteroaryl ring contains 1-4 heteroatoms such as N, O and S.
  • Non-limiting examples of 5 to 6-membered monocyclic heteroaryl rings include furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, pyrazolyl, pyrrolyl, imidazolyl, tetrazolyl, triazolyl, thienyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, and purinyl.
  • Non-limiting examples of 7 to 11-membered heteroaryl bicyclic heteroaryl rings include benzimidazolyl, quinolinyl, dihydro-2H-quinolinyl, isoquinolinyl, quinazolinyl, indazolyl, thieno[2,3-d]pyrimidinyl, indolyl, isoindolyl, benzofuranyl, benzopyranyl, benzodioxolyl, benzoxazolyl and benzothiazolyl.
  • halogen as used in the present specification shall be understood to mean bromine, chlorine, fluorine or iodine.
  • alkyl a non-limiting example would be -CH 2 CHF 2 , -CF 3 etc.
  • the compounds of the invention are only those which are contemplated to be 'chemically stable' as will be appreciated by those skilled in the art.
  • a compound which would have a 'dangling valency' , or a 'carbanion' are not compounds contemplated by the inventive methods disclosed herein.
  • the invention includes pharmaceutically acceptable derivatives of compounds depicted in Table 1.
  • a "pharmaceutically acceptable derivative” refers to any pharmaceutically acceptable salt or ester, or any other compound which, upon administration to a patient, is capable of providing (directly or indirectly) a compound useful for the invention, or a pharmacologically active metabolite or pharmacologically active residue thereof.
  • a pharmacologically active metabolite shall be understood to mean any compound of the invention capable of being metabolized enzymatically or chemically. This includes, for example, hydroxylated or oxidized derivative compounds of the invention.
  • Pharmaceutically acceptable salts include those derived from pharmaceutically acceptable inorganic and organic acids and bases.
  • acids examples include hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfuric, tartaric, acetic, citric, methanesulfonic, formic, benzoic, malonic, naphthalene-2- sulfuric and benzenesulfonic acids.
  • Other acids such as oxalic acid, while not themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds and their pharmaceutically acceptable acid addition salts.
  • Salts derived from appropriate bases include alkali metal (e.g., sodium), alkaline earth metal (e.g., magnesium), ammonium and N-(C T -C4 alkyl)4 + salts.
  • prodrugs of compounds of the invention include those compounds that, upon simple chemical transformation, are modified to produce compounds of the invention. Simple chemical transformations include hydrolysis, oxidation and reduction. Specifically, when a prodrug is administered to a patient, the prodrug may be transformed into a compound disclosed hereinabove, thereby imparting the desired pharmacological effect.
  • the invention also provides processes for making compounds of Formula (I).
  • R 1 , R 2 , R 3 , R 4 R 5 and n in the formulas below shall have the meaning of R 1 , R 2 , R 3 R 4 R 5 and n in Formula (I) of the invention described herein above.
  • reaction conditions and reaction times may vary depending on the particular reactants used. Unless otherwise specified, solvents, temperatures, pressures, and other reaction conditions may be readily selected by one of ordinary skill in the art. Specific procedures are provided in the Synthetic Examples section. Typically, reaction progress may be monitored by thin layer chromatography (TLC), if desired, and intermediates and products may be purified by chromatography on silica gel and/or by recrystallization.
  • TLC thin layer chromatography
  • an acid of formula II is coupled with an amine of formula III under standard coupling conditions, to provide a compound of formula IV.
  • Standard peptide coupling reactions known in the art see for example M. Bodanszky, 1984, The Practice of Peptide Synthesis, Springer- Verlag) may be employed in these syntheses.
  • An example of suitable coupling conditions is treatment of a solution of the carboxylic acid in a suitable solvent such as DMF with EDC, HOBT, TBTU, PyBOP and a base such as diisopropylethylamine, followed by the desired amine of formula III, to provide a compound of IV.
  • an acid of formula V is coupled with an amine of formula III under standard coupling conditions, as described in scheme 1 and in the examples, to provide a compound of Formula (I).
  • the intermediate acid of formula II may be prepared according to the method outlined in scheme 3
  • reaction of a nitro compound of formula VI with a diamino alkyl compound, in a suitable solvent provides the corresponding intermediate of formula VII. Protection of the amino group of intermediate VII followed by the reduction of the nitro group, under standard conditions, provides the corresponding amino compound of formula VIII. Cyclization of the intermediate of formula VIII using a reagent such as methyl trichloroacetimidate, in a suitable solvent provides cyclized trichloro compound of formula IX. Reaction of the trichloro compound of formula IX with sodium methoxide provides the acid of formula II.
  • the intermediate acid of formula V may be prepared according to the method outlined in scheme 4
  • the intermediate acid of formula V may be prepared according to the method outlined in scheme 5
  • the intermediate acid of formula V may be prepared according to the method outlined in scheme 6
  • the intermediate acid of formula V may be prepared according to the method outlined in scheme 7
  • Oxidation of compound XXIII provides the corresponding dioxide of formula XXIV.
  • Reaction of compound XXIV with compound XIX, in a suitable solvent, in the presence of a suitable base provides the intermediate of formula XXI.
  • Compound XXI is converted to the desired acid of formula V by the reaction scheme outlined in scheme 6. Retention times for the compounds are obtained on an HPLC system using the conditions shown in Table 2 below.
  • Step 1 Synthesis of Methyl 3-[(3-aminopropyl)amino]-4-nitrobenzoate
  • acetonitrile 200 ml
  • 1,3-diaminopropane 89.3 g, 1.21 mol
  • the solvent is evaporated, H 2 0 (100 mL) is added to the residue, and the mixture is extracted with EtOAc (5 x 100 mL).
  • EtOAc 5 x 100 mL
  • the combined organic layers are dried (Na 2 S0 4 ) and evaporated to afford the title compound (22.4 g, 80%) which is used in the next step without purification.
  • LCMS Method 1: 1.05 min, 254.58 (MH+).
  • Step 2 Synthesis of Methyl 3-( ⁇ 3-[(tert-butoxycarbonyl)amino]propyl ⁇ amino)-4- nitrobenzoate
  • Step 4 Synthesis of Methyl l- ⁇ 3-[(tert-butoxycarbonyl)amino]propyl ⁇ -2- (trichloromethyl)-lH-benzimidazole-6-carboxylate
  • methyl 4-amino-3-( ⁇ 3-[(tert- butoxycarbonyl)amino]propyl ⁇ amino)benzoate 4.7 g, 14.5 mmol
  • acetic acid 50 mL
  • methyl trichloroacetimidate 3.1 g, 17.4 mmol
  • Step 5 l- ⁇ 3-[(tert-Butoxycarbonyl)amino]propyl ⁇ -2-(trimethoxymethyl)-lH- benzimidazole-6-carboxylic acid
  • Step 1 Synthesis of l-(3-aminopropyl)-2-(methoxycarbonyl)-lH-benzimidazole-6- carboxylic acid hydrochloride
  • Step 2 Synthesis of l-Oxo-2,3,4,5-tetrahydro-lH-[l,4]diazepino[l,2- a]benzimidazole-8-carboxylic acid
  • Triethylamine (14.3 g, 141.7 mmol) is added to a solution of the crude l-(3- aminopropyl)-2-(methoxycarbonyl)-lH-benzimidazole-6-carboxylic acid hydrochloride (20 g, 47.2 mmol) in methanol (100 mL) and reaction mixture is refluxed for 1 h. The reaction mixture is cooled and acidified with 1M HCl. The solvent is evaporated and water is added. The resultant solid is collected by filtration and purified by acid-base neutralization using sodium bicarbonate and cone. HCl to afford the title compound (3.4 g, 30 %) as a solid.
  • Oxalyl chloride (4.60 mL), 53.6 mmol) is added to a stirred suspension of 3-fluoro-4- nitrobenzoic acid (5.11 g, 26.8 mmol) in CH 2 C1 2 (100 mL).
  • DMF 0.1 mL is added, and the solution stirred for 2 h at room temperature. The solvent is evaporated, and the residue is dissolved in CH 2 C1 2 (100 mL).
  • Benzyl alcohol (5.54 mL, 53.6 mmol) and pyridine (2 mL) are added and the solution stirred for 16 h.
  • Step 2 Synthesis of Benzyl 3-[(4-hydroxy-2-methylbutan-2-yl)amino]-4- nitrobenzoate A stirred solution of benzyl 3-fluoro-4-nitrobenzoate (2.67 g, 9.69 mmol) and 3-amino-3- methylbutan-l-ol (1.00 g, 9.69 mmol) in acetonitrile (20 mL) containing potassium carbonate (1.34 g, 9.69 mmol) is heated to 80 °C for 16 h.
  • Step 3 Synthesis of Benzyl 3-( ⁇ 4-[bis(tert-butoxycarbonyl)amino]-2-methylbutan-2- yl ⁇ amino)-4-nitrobenzoate
  • benzyl 3-[(4-hydroxy-2-methylbutan-2-yl)amino]-4-nitrobenzoate 395 mg, 1.10 mmol
  • di-ie/ -butyl iminodicarboxylate 367 mg, 1.65 mmol
  • triphenylphosphine 430 mg, 1.65 mmol
  • THF 5 mL
  • diisopropyl azodicarboxylate 0.34 mL, 1.65 mmol
  • Step 4 Synthesis of Benzyl 4-amino-3-( ⁇ 4-[bis(tert-butoxycarbonyl)amino]-2- methylbutan-2-yl ⁇ amino)benzoate
  • benzyl 3-( ⁇ 4-[bis(tert-butoxycarbonyl)amino]-2-methylbutan- 2-yl ⁇ amino)-4-nitrobenzoate 280 mg, 0.50 mmol
  • zinc dust 344 mg, 5.27 mmol
  • acetic acid (0.34 mL)
  • the mixture is stirred for 20 min, methanol (50 mL) is added and the mixture is filtered through Celite.
  • Step 5 Synthesis of l-( ⁇ 4-[Bis(tert-butoxycarbonyl)amino]-2-methylbutan-2-yl ⁇ -lH- benzimidazole-2,6-dicarboxylic acid 6-benzyl ester 2-methyl ester
  • Step 6 Synthesis of Benzyl 5,5-dimethyl-l-oxo-2,3,4,5-tetrahydro-lH- [l,4]diazepino[l,2-a]benzimidazole-8-carboxylate
  • Step 7 Synthesis of 5,5-Dimethyl-l-oxo-2,3,4,5-tetrahydro-lH-[l,4]diazepino[l,2- a]benzimidazole-8-carboxylc acid
  • Step 1 Synthesis of N-(6-Chloropyridin-2-yl)-2,2-dimethylpropionamide
  • 6-chloro-2-aminopyidine 50 g, 389 mmol
  • triethylamine 68 mL, 486 mmol
  • pivaloyl chloride 52 g, 428 mmol
  • the reaction mixture is stirred at ambient temperature for 16 h.
  • Saturated NH 4 CI solution (100 mL) is added and the mixture is extracted with CH 2 C1 2 (3 x 200 mL).
  • the combined organic layers are washed with saturated NaHC0 3 solution, dried (Na 2 S0 4 ) and evaporated to afford the title compound as an off-white solid (70 g, 86%) which is used in the next step without purification.
  • N-(6-Chloro-3-iodopyridin-2-yl)-2,2-dimethylpropionamide (33 g, 97 mmol) is dissolved in IN HC1 (300 mL) in the presence of catalytic amount of methanol (0.5 mL) at 0 °C.
  • the reaction mixture is heated at 110 °C for 5 h. After cooling, the reaction mixture is extracted with ethyl acetate (2 x 250 mL). The organic layers are separated and the solvent is evaporated to afford the title compound as a viscous liquid (24 g, 97%) which is used in the next step without purification.
  • Step 5 Synthesis of Ethyl 6-chloro-lH-pyrrolo[2,3-b]pyridine-2-carboxylate HC1 gas is bubbled through a solution of 6-chloro-lH-pyrrolo[2,3-b]pyridine-2- carboxylic acid (36 g, 183 mmol) in ethanol (500 mL) at 0 °C for 30 min. The reaction mixture is then heated at reflux for 16 h. The solvent is evaporated and the residue is diluted with CH 2 CI 2 and filtered. The filtrate is evaporated and the residue is washed with diethyl ether (2 x 250 mL). The organic layers are dried (Na 2 S0 4 ) and concentrated. The crude residue is purified by passing through the column of neutral alumina, eluting with 10% EtOAc/hexane to afford the title compound as a white solid (10 g, 25%).
  • Reagents are charged into a 600 mL autoclave in the following order: ethanol (350 mL), sodium acetate (17.0 g, 200 mmol), 6-chloro-lH-pyrrolo[2,3-b]pyridine-2-carboxylic acid ethyl ester (24 g, 107 mmol), l,l'-bis-(diphenylphosphino)ferrocene (2.5 g, 2.25 mmol [2.25 mol%]), and palladium acetate (180 mg, 0.75 mmol [0.75 mol %]).
  • the air in the autoclave is replaced with carbon monoxide and the pressure is adjusted to 250 psi.
  • the reaction is then heated to 110 °C for 15 h.
  • the reaction mixture is cooled to room temperature and is filtered through Celite.
  • the solvent is replaced with 500 mL EtOAc followed by 100 mL aqueous wash.
  • the organic layer is concentrated to 50 mL EtOAc and is then heated to 60 °C. After cooling to room temperature, the solids are filtered to afford 20 g of the title compound.
  • the mother liquor is concentrated and is purified by flash column chromatography using gradient elution of 20-60% ethyl acetate in hexanes to afford an additional 3.5 g of title compound which affords total of 23.5 g in 84% isolated yield.
  • Step 1 Synthesis of Ethyl 6-oxo-7,8,9,10-tetrahydro-6H-pyrido[3',2':4,5]pyrrolo[l,2- a] [ 1 ,4] diazepine-2-carboxylate
  • diethyl lH-pyrrolo[2,3-b]pyridine-2,6-dicarboxylate (Intermediate D, 2.00 g, 7.23 mmol) in NMP (20 mL) is added potassium carbonate (3.16 g, 22.9 mmol) and l-(3-bromopropyl)-2,2,5,5-tetramethyl-l-aza-2,5-disilacyclopentane (2.28 mL, 9.15 mmol).
  • Step 2 Synthesis of 6-Oxo-7,8,9,10-tetrahydro-6H-pyrido[3',2':4,5]pyrrolo[l,2- a] [ 1 ,4] diazepine-2-carboxylic acid
  • Step 1 Synthesis of tert-Butyl (3-hydroxy-2,2-dimethylpropyl)carbamate
  • a solution of 3-amino-2,2-dimethyl-l-propanol (1.50 g, 14.5 mmol) in CH 2 C1 2 (70 ml) is added di-tert-butyl dicarbonate (3.49 g, 16.0 mmol).
  • the mixture is stirred at room temperature for 16 h.
  • Saturated NH 4 C1 solution is added and the mixture is stirred for 10 min.
  • the layers are separated and the organic phase is washed with saturated NaHC0 3 solution and is dried (Na 2 S0 4 ) and concentrated in vacuo to afford the title compound as a white solid (3.40 g, quantitative).
  • Step 2 Synthesis of Diethyl l- ⁇ 3-[(tert-butoxycarbonyl)amino]-2,2-dimethylpropyl ⁇ - lH-pyrrolo[2,3-b]pyridine-2,6-dicarboxylate
  • tert-butyl (3-hydroxy-2,2-dimethylpropyl)carbamate (2.13 g, 10.5 mmol)
  • diethyl lH-pyrrolo[2,3-b]pyridine-2,6-dicarboxylate (Intermediate D, 2.50 g, 9.53 mmol)
  • triphenylphosphine 5.00 g, 19.1 mmol
  • Step 4 Synthesis of 9,9-Dimethyl-6-oxo-7,8,9,10-tetrahydro-6H- pyrido[3',2':4,5]pyrrolo[l,2-a][l,4]diazepine-2-carboxylic acid
  • Step 1 Synthesis of tert-Butyl (3-hydroxybutyl)carbamate
  • a stirred solution of 4-amino-butan-2-ol 1.0 g, 11.2 mmol
  • CH 2 CI 2 20 mL
  • di-tert-butyl dicarbonate 2.45 g, 11.2 mmol
  • the reaction mixture is stirred for 18 h.
  • the solution is washed with citric acid and saturated NaHC0 3 solution, dried (MgS0 4 ) and evaporated to afford the title compound as a colorless oil (2.1 g, 99%).
  • Step 2 Synthesis of tert-Butyl 6-methyl-l,2,3-oxathiazinane-3-carboxylate 2-oxide
  • Step 3 Synthesis of tert-Butyl 6-methyl-l,2,3-oxathiazinane-3-carboxylate 2,2- dioxide
  • the crude tert-butyl 6-methyl-l,2,3-oxathiazinane-3-carboxylate 2-oxide (2.52 g, 10.7 mmol) is dissolved in acetonitrile (25 mL) and H 2 0 (15 mL) is added. The solution is cooled in an ice bath and sodium periodate (3.4 g, 16.1 mmol) is added in one portion. After 5 min, the pH is adjusted to 7-8 by addition of saturated Na 2 HP0 4 solution. Then RuCl 3 (22 mg, 0.11 mmol) in H 2 0 (0.5 mL) is added. The pH is kept between 6 and 9 by addition of Na 2 HP0 4 solution.
  • Step 4 Synthesis of Diethyl l- ⁇ 4-[(tert-butoxycarbonyl)amino]butan-2-yl ⁇ -lH- pyrrolo[2,3-b]pyridine-2,6-dicarboxylate
  • Step 5 Synthesis of Diethyl l-(4-aminobutan-2-yl)-lH-pyrrolo[2,3-b]pyridine-2,6- dicarboxylate
  • Step 1 Synthesis of 3-Aminobutan-2-ol Ammonium formate (9.0 g, 142.9 mmol) is added to a solution of 3-nitro-butan-2-ol (2.5 g, 21.0 mmol) in methanol (20 mL). 10% Palladium on carbon (250 mg) is then added as a slurry in methanol. The reaction mixture is stirred at room temperature for 18 h. Then Celite is added and the mixture is filtered though a plug of more Celite. The solid is washed again with methanol and the filtrates are combined and concentrated to afford the crude title compound (2.42 g, >99%) which is used in the next step without purification.
  • Step 2 Synthesis of tert-Butyl (3-hydroxybutan-2-yl)carbamate
  • 3-aminobutan-2-ol (2.42 g, 21.7 mmol) in CH 2 CI 2 (20 mL)
  • di-tert-butyl dicarbonate (4.7 g, 21.4 mmol) in CH 2 CI 2 (20 mL).
  • the reaction mixture is stirred for 18 h and then the solution is washed with 1M NaHS0 4 and NaHC0 3 .
  • the organic layer is separated, dried (MgS0 4 ) and concentrated to afford the title compound (4.33 g, >99%) as a colorless oil which was used in the next step without purification.
  • Step 3 Synthesis of tert-Butyl 4,5-dimethyl-l,2,3-oxathiazolidine-3-carboxylate 2- oxide
  • thionyl chloride 4.1 mL, 56.8 mmol
  • acetonitrile 30 mL
  • tert-butyl (3-hydroxybutan-2-yl)carbamate 4.3 g, 22.7 mmol
  • acetonitrile 40 mL
  • 4-dimethylamino pyridine (278 mg, 2.3 mmol) is added.
  • Step 4 Synthesis of tert-Butyl 4,5-dimethyl-l,2,3-oxathiazolidine-3-carboxylate 2,2- dioxide tert-Butyl 4,5-dimethyl-l,2,3-oxathiazolidine-3-carboxylate 2-oxide (4.7 g, 20.0 mmol) is dissolved in acetonitrile (50 mL) and H 2 0 (30 mL) is added. The reaction mixture is cooled to 0 °C and sodium periodate (6.4 g, 30.0 mmol) is added. After 5 min, the pH of the mixture is adjusted to 7-8 by addition of saturated Na 2 HP0 4 solution.
  • Step 5 Synthesis of Diethyl l- ⁇ 3-[(tert-butoxycarbonyl)amino]butan-2-yl ⁇ -lH- pyrrolo[2,3-b]pyridine-2,6-dicarboxylate
  • Diethyl lH-pyrrolo[2,3-b]pyridine-2,6-dicarboxylate (Intermediate D, 3.40 g, 13.0 mmol) in DMF (15 mL) cooled to 0 °C is added 60% sodium hydride in mineral oil (570 mg, 14.3 mmol).
  • the mixture is stirred at 0 °C for 20 min after which a solution of tert-butyl 4,5-dimethyl-l,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide (5.35 g, 14.3 mmol) in DMF (10 mL) is added.
  • the mixture is stirred at 0 °C for 30 min after which the reaction was allowed to warm and stir at ambient temperature overnight.
  • the reaction is quenched with H 2 0 and was stirred for 15 min.
  • the mixture is extracted with ethyl acetate and the combined organic phases are washed with brine, and are dried (Na 2 S0 4 ).
  • Step 7 Synthesis of 8,9-Dimethyl-6-oxo-6,7,8,9- tetrahydropyrido[3',2':4,5]pyrrolo[l,2-a]pyrazine-2-carboxylic acid
  • Step 8 Synthesis of Ethyl ds-8,9-dimethyl-6-oxo-6,7,8,9- tetrahydropyrido[3',2':4,5]pyrrolo[l,2-a]pyrazine-2-carboxylate and Ethyl trans- 8,9-dimethyl-6-oxo-6,7,8,9-tetrahydropyrido[3',2':4,5]pyrrolo[l,2-a]pyrazine-2- carboxylate
  • Step 9a Synthesis of c s-8,9-Dimethyl-6-oxo-6,7,8,9- tetrahydropyrido[3',2':4,5]pyrrolo[l,2-a]pyrazine-2-carboxylic acid
  • Step 9b Synthesis of tra «s-8,9-Dimethyl-6-oxo-6,7,8,9- tetrahydropyrido[3',2':4,5]pyrrolo[l,2-a]pyrazine-2-carboxylic acid
  • a suspension of ethyl trans-8,9-di et y ⁇ -6-oxo-6,T,8,9- tetrahydropyrido[3',2':4,5]pyrrolo[l,2-a]pyrazine-2-carboxylate 702 mg, 2.44 mmol
  • ethanol 20 mL
  • 1M aqueous NaOH solution (6.11 mL, 6.11 mmol
  • Step 1 Synthesis of Diethyl l-(l-cyanoethyl)-lH-pyrrolo[2,3-b]pyridine-2,6- dicarboxylate
  • Step 2 Synthesis of Ethyl 9-methyl-6-oxo-6,7,8,9- tetrahydropyrido[3',2':4,5]pyrrolo[l,2-a]pyrazine-2-carboxylate
  • Step 3 Synthesis of 9-Methyl-6-oxo-6,7,8,9-tetrahydropyrido[3',2':4,5]pyrrolo[l,2- a]pyrazine-2-carboxylic acid
  • Step 1 Synthesis of tert-Butyl [(2S)-2-hydroxypropyl]carbamate
  • Step 2 Synthesis of tert-Butyl (5S)-5-Methyl-l,2,3-oxathiazolidine-3-carboxylate 2- oxide
  • Step 3 Synthesis of tert-Butyl (5S)-5-methyl-l,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide
  • a solution of tert-butyl (5S)-5-methyl-l,2,3-oxathiazolidine-3-carboxylate 2-oxide (5.7 g, 25.8 mmol) in acetonitrile (60 mL) and H 2 0 (30 mL) is added sodium periodate (8.3 g, 38.7 mmol). After 5 min, a few crystals of R11CI 3 are added.
  • the reaction is stirred for 3 hours and the resulting thick slurry is diluted with H 2 0 (100 mL) and ethyl acetate (20 mL) and passed through a bed of Celite, rinsing with additional EtOAc. The filtrate is concentrated to remove the organic solvents and the resulting solid is isolated by filtration to afford the title compound (6.0 g, 97%).
  • Step 4 Synthesis of Diethyl l- ⁇ (2S)-l-[(tert-butoxycarbonyl)amino]propan-2-yl ⁇ - lH-pyrrolo[2,3-b]pyridine-2,6-dicarboxylate
  • DMF dimethyl methyl ether
  • Step 4 Synthesis of Diethyl l- ⁇ (2S)-l-[(tert-butoxycarbonyl)amino]propan-2-yl ⁇ - lH-pyrrolo[2,3-b]pyridine-2,6-dicarboxylate
  • Step 5 Synthesis of Diethyl l-[(2S)-l-aminopropan-2-yl]-lH-pyrrolo[2,3-b]pyridine- 2,6-dicarboxylate
  • Diethyl l- ⁇ (2S)-l-[(tert-butoxycarbonyl)amino]propan-2-yl ⁇ -lH- pyrrolo[2,3-b]pyridine-2,6-dicarboxylate 3.00 g, 7.15 mmol
  • CH 2 C1 2 20 mL
  • TFA 10 mL
  • Step 6 Synthesis of (9R)-9-Methyl-6-oxo-6,7,8,9- tetrahydropyrido[3',2':4,5]pyrrolo[l,2-a]pyrazine-2-carboxylic acid
  • Step 3 Synthesis of l-(Propan-2-yl)-lH-benzimidazol-2-amine; hydrobromide
  • N-(propan-2-yl)benzene-l,2-diamine 552 mg, 3.4 mmol
  • ethanol 10 mL
  • 3M solution of cyanogen bromide 1.35 mL, 4.04 mmol
  • the reaction is stirred overnight and then concentrated.
  • the crude residue is triturated with diethyl ether and the suspension is filtered to afford the title compound (870 mg, 92%) as a purple solid.
  • Step 1 Synthesis of tert-butyl [2-(cyclopentylcarbamoyl)-l-methyl-lH-imidazol-4- yl]carbamate
  • Step 2 Synthesis of l-(Tetrahydro-2H-pyran-4-yl)-lH-pyrazol-5-amine
  • Step 4 Synthesis of l-(Tetrahydro-2H-pyran-4-yl)-lH-pyrazolo[3,4-b]pyridin-5- amine Iron (2.41 g, 42.3 mmol) and ammonium chloride (2.58 g, 48.4 mmol) are added to a solution of 5-nitro-l-(tetrahydro-2H-pyran-4-yl)-lH-pyrazolo[3,4-b]pyridine (3 g, 12mmol) in ethanol/THF/H 2 0 (4:2: 1, 35 mL). The mixture is heated at 100 °C for 2 h. The iron is removed by filtration through pad of Celite ® and the filtrate was evaporated under reduced pressure. The residue is purified by flash column chromatography using a gradient of 70% ethyl acetate/petroleum ether to afford the title compound as an off- white solid (2.85g, 93%).
  • l-(Tetrahydro-furan-3-ylmethyl)-lH-pyrazolo[3,4-b]pyridin-5-ylamine is synthesized using a similar procedure used to prepare (l-(Tetrahydro-pyran-4-yl)-lH-pyrazolo[3,4- b]pyridin-5-ylamine (Intermediate P), replacing tetrahydropyran-4-one with tetrahydro- furan-3-carbaldehyde in Step 1.
  • Step 1 Synthesis of 4-(5-Chloro-2-nitrobenzyl)morpholine
  • morpholine 2.8 mL, 32.3 mmol
  • tetrahydrofuran 100 mL
  • 5-chloro-2-nitrobenzaldehyde 5 g, 26.9 mmol
  • sodium triacetoxyborohydride 11.4 g, 53.9 mmol
  • HO Ac 3.2 mL, 53.9 mmol
  • Step 6 Synthesis of 5-Chloro-3-(morpholin-4-ylmethyl)benzene-l,2-diamine
  • tin (II) chloride 1.1 g, 6 mmol
  • 4-chloro-2-(morpholin-4-ylmethyl)-6-nitroaniline 543 mg, 2 mmol
  • the reaction is stirred for 1 hour.
  • the thick slurry is filtered and the filter cake rinsed with HCl.
  • the filter cake is dissolved in H 2 0 (10 mL) and treated with 2M aqueous K 2 C0 3 and extracted with CH 2 C1 2 .
  • the organic layer is separated, dried (Na 2 S0 4 ) and concentrated to afford the title compound (458 mg, 95%) as an oil.
  • Step 1 Synthesis of (2-Phenyl-l,3-dioxolan-2-yl)acetonitrile
  • 3-oxo-3-phenylpropanenitrile 10 g, 69 mmol
  • PTSA 27 mg, 1.37 mmol
  • toluene 120 mL
  • ethylene glycol 120 mL, 2057 mmol
  • the azeotropic mixture is heated at 150 °C for 14 h.
  • the solvent is evaporated under reduced pressure and the residue is washed with 10% aqueous NaOH solution.
  • the aqueous layer is extracted with diethyl ether (2 x 100 mL) and the combined organic layers are dried (Na 2 S0 4 ) and evaporated to provide the crude compound.
  • the crude material is purified over neutral alumina eluting with 1% of ethyl acetate/hexane to afford the title compound as an off-white solid (10 g, 77%).
  • Step 3 Synthesis of 5-Phenyl-l,2-oxazol-3-amine
  • Ethanol 125 mL
  • H 2 0 25 mL
  • N-hydroxy-2-(2-phenyl-l,3-dioxolan-2- yl)ethanimidamide 7 g, 32 mmol.
  • the pH is adjusted to 1 with the addition concentrated HC1 and the reaction mixture is heated at 90 °C for 2 h.
  • the solvent is evaporated to dryness and the resulting residue is neutralized using phosphate buffer.
  • the mixture is extracted with ethyl acetate and the combined organic phases are dried (Na 2 S0 4 ) and concentrated in vacuo.
  • the crude residue is purified over neutral alumina eluting with 30% ethyl acetate/hexane to afford the title compound as an off-white solid (1.7 g, 34%).
  • Step 1 Synthesis of 6- Chloro-N ⁇ 2 ⁇ -ethylpyridine-2,3-diamine
  • 6-chloro-N-ethyl-3-nitropyridin-2-amine (1.82 g, 9.04 mmol) in ethanol (20 mL)
  • iron powder (2.52 g, 45.2 mmol)
  • ammonium chloride (2.42 g, 45.2 mmol)
  • H 2 0 8 mL
  • the mixture is heated in a microwave reactor at 140 °C for 30 min.
  • the mixture is diluted with EtOAc, filtered and evaporated to afford the title compound as a brown oil (1.55 g, 100%) which was used in the next step without purification.
  • Step 2 Synthesis of 5-Chloro-3-ethyl-3H-imidazo[4,5-b]pyridin-2-amine
  • a solution of 6-chloro-N ⁇ 2 ⁇ -ethylpyridine-2,3-diamine (401 mg, 2.34 mmol) in ethanol (10 mL) is added a 3M solution of cyanogen bromide in CH 2 C1 2 (0.93 mL, 2.8 mmol) and the resulting solution is stirred for 6 h at room temperature.
  • the solution is basified with ammonia in methanol and evaporated.
  • the residue is purified via flash column chromatography using a gradient elution of 0-15% CH 2 Cl 2 /methanol containing 1% NH 4 OH to afford the title compound (212 mg, 46%).
  • Step 1 Synthesis of 3-Oxo-4-phenylbutanenitrile
  • a solution of methyl phenylacetate (2.50 g, 16.6 mmol) and anhydrous acetonitrile (1.74 mL, 33.3 mmol) in THF (40 mL) dropwise.
  • the mixture is stirred at reflux for 6 h, then cooled to room temperature and stirred an additional 16 h.
  • the reaction is quenched with H 2 0 and is stirred for 10 min, after which the mixture is diluted with ethyl acetate and saturated aqueous NaHC0 3 solution.
  • Step 1 Synthesis of tert-Butyl ⁇ 3-[6-(pyridin-3-ylcarbamoyl)-2-(trimethoxymethyl)- lH-benzimidazol-l-yl]propyl ⁇ carbamate
  • Step 2 Synthesis of l-Oxo-N-(pyridin-3-yl)-2,3,4,5-tetrahydro-lH- [l,4]diazepino[l,2-a]benzimidazole-8-carboxamide
  • the organic layer was dried (MgS0 4 ) and evaporated.
  • the crude product was purified via preparative HPLC. The major peak was collected by passing the HPLC fractions, without concentrating, directly through an SCX cartridge (Silicycle tosic acid, lg). The cartridge was washed with methanol, then CH 2 Cl 2 /methanol (50:50). Finally, the product was eluted with CH 2 Cl 2 /methanol containing 1% NH 4 OH. The solution containing product was evaporated to afford the title compound (13 mg, 22%).
  • Example 2 is synthesized according to the procedure for Example 1, substituting commercially available reagents.
  • Examples 4-17 are synthesized according to the procedure for Example 2, substituting either commercially available reagents or the appropriate intermediates described above.
  • Example 21 is synthesized according to the procedure for Example 20, substituting commercially available reagents.
  • Step 1 Synthesis of l-oxo-N-[3-(l-trityl-lH-imidazol-4-yl)phenyl]-2,3,4,5- tetrahydro-lH-[l,4]diazepino[l,2-a]benzimidazole-8-carboxamide
  • Examples 24-78 are synthesized according to the procedure for Example 23, substituting either commercially available reagents or the appropriate intermediates described above.
  • Example 80 N-(5-Methyl-l,2-oxazol-3-yl)-6-oxo-7,8,9,10-tetrahydi pyrido[3',2':4,5]pyrrolo[l,2-a][l,4]diazepine-2-carboxamide
  • Examples 88-93 are synthesized according to the procedure for Example 90, substituting either commercially available reagents or the appropriate intermediates described above.
  • Examples 95-100 are synthesized according to the procedure for Example 97, substituting either commercially available reagents or the appropriate intermediates described above.
  • the mixture is stirred at 60 °C under a continuous stream of nitrogen, which slowly concentrates the solution. After being stirred for 5 h, the mixture was warmed to 80 °C and stirred overnight.
  • the reaction mixture is diluted with methanol (0.5 mL) and ether (1 mL). The resultant precipitate is collected by filtration to afford the title compound as a dark yellow solid (21 mg, 34%).
  • Examples 102 and 103 are synthesized according to the procedure for Example 102, substituting either commercially available reagents or the appropriate intermediates described above.
  • Example 104 N-[2-(cyclopentylcarbamoyl)-l-methyl-lH-imidazol-4-yl]-6-oxo- 7,8,9,10-tetrahydro-6H-pyrido[3',2':4,5]pyrrolo[l,2-a][l,4]diazepine-2-carboxamide
  • Step 1 Synthesis of l-methyl-4- ⁇ [(6-oxo-7,8,9,10-tetrahydro-6H- pyrido[3 ⁇ 2':4,5]pyrrolo[l,2-a][l,4]diazepin-2-yl)carbonyl]amino ⁇ -lH-imidazole-2- carboxylic acid
  • Step 2 Synthesis of N-[2-(cyclopentylcarbamoyl)-l-methyl-lH-imidazol-4-yl]-6- oxo-7,8,9,10-tetrahydro-6H-pyrido[3',2':4,5]pyrrolo[l,2-a][l,4]diazepine-2- carboxamide
  • Example 105 N-[3-(lH-imidazol-4-yl)phenyl]-6-oxo-7,8,9,10-tetrahyd] pyrido[3',2':4,5]pyrrolo[l,2-a][l,4]diazepine-2-carboxamide
  • Step 1 Synthesis of 6-oxo-N-[3-(l-trityl-lH-imidazol-4-yl)phenyl]-7,8,9,10- tetrahydro-6H-pyrido[3',2':4,5]pyrrolo[l,2-a][l,4]diazepine-2-carboxamide
  • Step 2 Synthesis of N-[3-(lH-imidazol-4-yl)phenyl]-6-oxo-7,8,9,10-tetrahydro-6H- pyrido[3',2':4,5]pyrrolo[l,2-a][l,4]diazepine-2-carboxamide
  • Human RSK2 protein purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP.
  • Kinase Glo Plus Promega
  • the assay is performed using 0.75 nM His-RSK2, 0.75 ⁇ ATP and 1.0 ⁇ S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog # 12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl 2 , 5 mM MnCl 2 , 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 ⁇ Na 3 V0 4 , 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO.
  • the DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%.
  • the assay is performed in a 384 well, white, non-binding plate (Corning, catalogue#3574). Solutions of test compounds (10 ⁇ ) are transferred to a dry assay plate, followed by addition of 20 ⁇ ⁇ kinase and 20 ⁇ ⁇ ATP + Substrate Peptide 1 described above. The kinase reaction mixture is incubated for 90 minutes at 28 °C followed by addition of 30 ⁇ ⁇ of ATP detection reagent for 15 minutes at room temperature. The relative light unit (RLU) signal is measured on a LJL Analyst (Molecular Devices) in luminescence mode using 384 aperture. The RLU signals were converted to percent of control (POC) values using the formula:
  • Signal is the test well RLU signal
  • BCTRL is the average of background (negative control), which consists of ATP + peptide and compound buffer, well signals on the plate
  • PCTRL is the average of positive control, which consists of kinase, ATP + peptide, and compound buffer, well signals on the plate.
  • POC as a function of test compound concentration are fitted to a 4-parameter logistic equation of the form:
  • HLR-CREB cells cAMP Response Element Binding
  • RSK2 RSK2 in cells.
  • a cell monolayer of exponentially growing HLR-CREB cells (PathDetect® HeLa Luciferase Reporter CREB cells, Stratagene) is prepared by the following method. In a 100 mm culture dish, 7.5 x 10 5 HLR-CREB cells are added to 10 mL culture medium consisting of RPMI-1640, 10% heat inactivated FCS, 2 mM glutamine, and 50 ⁇ g/mL gentamycin. The cells are allowed to adhere overnight, at which point 6 mL of medium is removed.
  • the cell monolayer is transfected using Effectene (Quiagen) with RSK2 by the following method.
  • a mixture of DNA, pCMV6-XL-RSK2 (1.0 ⁇ g) and pCDNA 3.1 (1.0 ⁇ g) is added to 300 ⁇ ⁇ DNA-condensation buffer.
  • the complexes are formed by addition of 16 ⁇ ⁇ enhancer, and the mixture is incubated for 5 minutes at room temperature.
  • 60 ⁇ L ⁇ Effectene is added, and the mixture is incubated for an additional 10 minutes at room temperature.
  • the final volume is adjusted to 2.0 mL with complete media, and added to the cell monolayer.
  • Five hours after transfection, the cells are plated into white 96 well culture plates (Greiner Bio-One 655083).
  • AlamarBlue results are represented as the percent fluorescent units relative to the control measured in the absence of inhibitors (POC).
  • Each data point represents an average of triplicate observations.
  • RSK2 (IC 50 ) activity of Examples 1 to 105 are shown in Table 4 below.
  • the compounds of the invention are effective inhibitors of RSK2. Therefore, in one embodiment of the invention, there is provided methods of treating RSK2 regulated disorders using compounds of the invention. In another embodiment, there is provided methods of treating cardiovascular, inflammatory, allergic, pulmonary and fibrotic diseases, renal diseases and cancer using compounds of the invention.
  • RSK2 activity is an attractive means for preventing and treating a variety of diseases mediated by RSKs. These include:
  • Cardiovascular diseases including atherosclerosis, myocardial infarction, stroke, aortic aneurysm, sickle cell crisis, ischemia-reperfusion injury, pulmonary arterial hypertension and sepsis;
  • Allergic diseases including asthma, allergic rhinitis, rhinosinusitis, atopic dermatitis and urticaria; Fibrotic diseases including airway remodeling in asthma, idiopathic pulmonary fibrosis, scleroderma, asbestosis;
  • Pulmonary syndromes including adult respiratory distress syndrome, viral bronchiolitis, obstructive sleep apnea, chronic obstructive pulmonary disease, cystic fibrosis, and bronchopulmonary dysplasia;
  • Inflammatory diseases including rheumatoid arthritis, osteoarthritis, gout, glomerulonephritis, interstitial cystitis, psoriasis, inflammatory bowel disease systemic lupus erythematosus, transplant rejection; and
  • Cancer including solid tumors, leukemias and lymphomas.
  • Renal diseases such as glomerulonephritis.
  • a therapeutically effective dose will generally be in the range from about 0.01 mg to about 100 mg/kg of body weight per dosage of a compound of the invention; preferably, from about 0.1 mg to about 20 mg/kg of body weight per dosage.
  • the dosage range would be from about 0.7 mg to about 7000 mg per dosage of a compound of the invention, preferably from about 7.0 mg to about 1400 mg per dosage.
  • Some degree of routine dose optimization may be required to determine an optimal dosing level and pattern.
  • the active ingredient may be administered from 1 to 6 times a day.
  • the compounds of the invention are typically administered in the form of a pharmaceutical composition.
  • Such compositions can be prepared using procedures well known in the pharmaceutical art and comprise at least one compound of the invention.
  • the compounds of the invention may also be administered alone or in combination with adjuvants that enhance stability of the compounds of the invention, facilitate administration of pharmaceutical compositions containing them in certain embodiments, provide increased dissolution or dispersion, increased antagonist activity, provide adjunct therapy, and the like.
  • the compounds according to the invention may be used on their own or in conjunction with other active substances according to the invention, optionally also in conjunction with other pharmacologically active substances.
  • the compounds of this invention are administered in a therapeutically or pharmaceutically effective amount, but may be administered in lower amounts for diagnostic or other purposes.
  • Administration of the compounds of the invention, in pure form or in an appropriate pharmaceutical composition can be carried out using any of the accepted modes of administration of pharmaceutical compositions.
  • administration can be, for example, orally, buccally (e.g., sublingually), nasally, parenterally, topically, transdermally, vaginally, or rectally, in the form of solid, semi-solid, lyophilized powder, or liquid dosage forms, such as, for example, tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aerosols, or the like, preferably in unit dosage forms suitable for simple administration of precise dosages.
  • the pharmaceutical compositions will generally include a conventional pharmaceutical carrier or excipient and a compound of the invention as the/an active agent, and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, diluents, vehicles, or combinations thereof.
  • Such pharmaceutically acceptable excipients, carriers, or additives as well as methods of making pharmaceutical compositions for various modes or administration are well-known to those of skill in the art. The state of the art is evidenced, e.g., by Remington: The Science and Practice of Pharmacy, 20th Edition, A.
  • the forms of the compounds of the invention utilized in a particular pharmaceutical formulation will be selected (e.g., salts) that possess suitable physical characteristics (e.g., water solubility) that are required for the formulation to be efficacious.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des composés de formule (I) et leurs sels pharmaceutiquement acceptables, où R1, R2, R3, R4, R5 et n sont tels que définis ici. L'invention concerne également des compositions pharmaceutiques comprenant ces composés, des procédés d'utilisation de ces composés dans le traitement de diverses maladies et divers troubles, et des procédés de préparations de ces composés et d'intermédiaires utiles dans ces procédés.
PCT/US2010/058482 2009-12-07 2010-12-01 Composés hétérocycliques contenant un cœur pyrrolopyridine ou benzimidazole WO2011071725A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP10788192.2A EP2509979B1 (fr) 2009-12-07 2010-12-01 Composés hétérocycliques contenant un noyau pyrrolopyridine ou benzimidazole
JP2012543150A JP5643332B2 (ja) 2009-12-07 2010-12-01 ピロロピリジンまたはベンゾイミダゾールコアを含有する複素環化合物
US13/513,973 US9073926B2 (en) 2009-12-07 2010-12-01 Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26718109P 2009-12-07 2009-12-07
US61/267,181 2009-12-07

Publications (1)

Publication Number Publication Date
WO2011071725A1 true WO2011071725A1 (fr) 2011-06-16

Family

ID=43446402

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/058482 WO2011071725A1 (fr) 2009-12-07 2010-12-01 Composés hétérocycliques contenant un cœur pyrrolopyridine ou benzimidazole

Country Status (4)

Country Link
US (1) US9073926B2 (fr)
EP (1) EP2509979B1 (fr)
JP (1) JP5643332B2 (fr)
WO (1) WO2011071725A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006245B2 (en) 2012-03-16 2015-04-14 Vitae Pharmaceuticals, Inc. Liver X receptor modulators
CN104557666A (zh) * 2015-01-16 2015-04-29 烟台贝森医药科技有限公司 一种合成3-酞酰亚胺-2-氧代丁醛-1,2-双缩氨基硫脲的新方法
US9073931B2 (en) 2012-03-16 2015-07-07 Vitae Pharmaceuticals, Inc. Liver X receptor modulators
JP2015528435A (ja) * 2012-08-10 2015-09-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ピラゾールカルボキサミド化合物、組成物及び使用方法
WO2017141116A1 (fr) 2016-02-19 2017-08-24 Phoenix Molecular Designs Dérivés de carboxamide utiles en tant qu'inhibiteurs de rsk
WO2018095953A1 (fr) 2016-11-23 2018-05-31 Bayer Cropscience Aktiengesellschaft Dérivés de 2-[3-(alkylsulfonyl)-2h-indazol-2-yl]-3h-imidazo[4,5-b]pyridine et composés similaires utilisés comme pesticides
US10246466B2 (en) 2014-01-24 2019-04-02 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
US10316044B2 (en) 2015-07-02 2019-06-11 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4636847B2 (ja) 2004-10-13 2011-02-23 株式会社ロッテ 全粒粉からなる小麦粉の加工方法及びその加工方法により得られた加工小麦粉並びにその加工小麦粉を使用した食品
JP5643332B2 (ja) 2009-12-07 2014-12-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピロロピリジンまたはベンゾイミダゾールコアを含有する複素環化合物
EP2978440B1 (fr) 2013-03-27 2019-10-02 Cedars-Sinai Medical Center Traitement de la fibrose par inhibition de tl1a et diagnostic de fibrose par detection de li31ra
WO2022251597A1 (fr) 2021-05-28 2022-12-01 Verge Analytics, Inc. Méthodes de traitement de troubles neurologiques avec des modulateurs de la protéine ribosomale s6 kinase alpha-1 (rsk1) et de la protéine ribosomale s6 kinase alpha-3 (rsk2)
CN117186098A (zh) * 2022-06-07 2023-12-08 上海科恩泰生物医药科技有限公司 一种具有rsk抑制作用的羧酰胺衍生物、包含其的药物组合物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009040512A2 (fr) * 2007-09-27 2009-04-02 University Court Of The University Of Dundee Modulation de rsk

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6027A (en) * 1849-01-09 Rotary blacksmith s twyer
US7790712B2 (en) 2005-03-17 2010-09-07 Boehringer Ingelheim Pharmaceutical, Inc. Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors
JP2013512952A (ja) * 2009-12-07 2013-04-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング インドールコアを含有する複素環化合物
JP5643332B2 (ja) 2009-12-07 2014-12-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピロロピリジンまたはベンゾイミダゾールコアを含有する複素環化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009040512A2 (fr) * 2007-09-27 2009-04-02 University Court Of The University Of Dundee Modulation de rsk

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Handbook of Pharmaceutical Additives", 1995
"Handbook of Pharmaceutical Excipients", 2000, AMERICAN PHARMACEUTICAL ASS'N
"Remington: The Science and Practice of Pharmacy", 2000, LIPPINCOTT WILLIAMS & WILKINS
FRIEDERIKE CUELLO; ANDREW K. SNABAITIS; MICHAEL S. COHEN; JACK TAUNTON; METIN AVKIRAN, MOL PHARMACOL, vol. 71, 2007, pages 799 - 806
H.C. ANSEL; N.G. POPOVISH: "Pharmaceutical Dosage Forms and Drug Delivery Systems", 1990
NAOYA MAEKAWA; JUN-ICHI ABE; TETSURO SHISHIDO; SEIGO ITOH; BO DING; VIRENDRA K: "Circulation", vol. 113, 2006, article "Sharma, Shey-Shing Sheu", pages: 2516 - 2523

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9814715B2 (en) 2012-03-16 2017-11-14 Vitae Pharamceuticals, Inc. Liver X receptor modulators
US9006244B2 (en) 2012-03-16 2015-04-14 Vitae Pharmaceuticals, Inc. Liver X receptor modulators
US9006245B2 (en) 2012-03-16 2015-04-14 Vitae Pharmaceuticals, Inc. Liver X receptor modulators
US9073931B2 (en) 2012-03-16 2015-07-07 Vitae Pharmaceuticals, Inc. Liver X receptor modulators
US9388190B2 (en) 2012-03-16 2016-07-12 Vitae Pharmaceuticals, Inc. Liver X receptor modulators
US9416135B2 (en) 2012-03-16 2016-08-16 Vitae Pharmaceuticals, Inc. Liver X receptor modulators
US9707232B2 (en) 2012-03-16 2017-07-18 Vitae Pharmaceuticals, Inc. Liver X receptor modulators
JP2015528435A (ja) * 2012-08-10 2015-09-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ピラゾールカルボキサミド化合物、組成物及び使用方法
US10618912B2 (en) 2014-01-24 2020-04-14 Turning Point Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
US10246466B2 (en) 2014-01-24 2019-04-02 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
CN104557666A (zh) * 2015-01-16 2015-04-29 烟台贝森医药科技有限公司 一种合成3-酞酰亚胺-2-氧代丁醛-1,2-双缩氨基硫脲的新方法
US10316044B2 (en) 2015-07-02 2019-06-11 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
EP3416964A4 (fr) * 2016-02-19 2019-09-18 Phoenix Molecular Designs Dérivés de carboxamide utiles en tant qu'inhibiteurs de rsk
CN109071542A (zh) * 2016-02-19 2018-12-21 凤凰分子设计公司 可用作rsk抑制剂的羧酰胺衍生物
JP2019505541A (ja) * 2016-02-19 2019-02-28 フェニックス モレキュラー デザインズ Ｒｓｋ阻害剤として有用なカルボキサミド誘導体
WO2017141116A1 (fr) 2016-02-19 2017-08-24 Phoenix Molecular Designs Dérivés de carboxamide utiles en tant qu'inhibiteurs de rsk
US10081632B2 (en) 2016-02-19 2018-09-25 Phoenix Molecular Designs Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-α]pyrazine-2-carboxamides as RSK inhibitors
US9771366B2 (en) 2016-02-19 2017-09-26 Phoenix Molecular Design Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamides as RSK inhibitors
US10758530B2 (en) 2016-02-19 2020-09-01 Phoenix Molecular Designs Carboxamide derivatives useful as rsk inhibitors
EP3848373A1 (fr) 2016-02-19 2021-07-14 Phoenix Molecular Designs Dérivés de carboxamide de n-(1-((heterocyclyl)methyl)-1h-pyrazol-4-yl)-6-oxo-6,7,8,9- tetrahydropyrido[3',2':4,5]pyrrolo[l,2-a]pyrazine-2 en tant qu'inhibiteurs de kinase p90 ribosomale s6 (rsk) pour le traitement du cancer
CN109071542B (zh) * 2016-02-19 2021-07-20 凤凰分子设计公司 可用作rsk抑制剂的羧酰胺衍生物
CN113620950A (zh) * 2016-02-19 2021-11-09 凤凰分子设计公司 可用作rsk抑制剂的羧酰胺衍生物
AU2017220738B2 (en) * 2016-02-19 2022-02-24 Phoenix Molecular Designs Carboxamide derivatives useful as RSK inhibitors
WO2018095953A1 (fr) 2016-11-23 2018-05-31 Bayer Cropscience Aktiengesellschaft Dérivés de 2-[3-(alkylsulfonyl)-2h-indazol-2-yl]-3h-imidazo[4,5-b]pyridine et composés similaires utilisés comme pesticides

Also Published As

Publication number Publication date
US9073926B2 (en) 2015-07-07
US20130137680A1 (en) 2013-05-30
EP2509979B1 (fr) 2016-05-25
JP5643332B2 (ja) 2014-12-17
EP2509979A1 (fr) 2012-10-17
JP2013512953A (ja) 2013-04-18

Similar Documents

Publication Publication Date Title
EP2509979B1 (fr) Composés hétérocycliques contenant un noyau pyrrolopyridine ou benzimidazole
JP7300460B2 (ja) 置換１，２－ジヒドロ－３Ｈ－ピラゾロ［３，４－ｄ］ピリミジン－３－オン
ES2898698T3 (es) Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa Rho (ROCK)
TWI471326B (zh) 作為ｃＦＭＳ抑制劑之經取代之Ｎ－（１Ｈ－吲唑－４－基）咪唑［１，２－ａ］吡啶－３－羧醯胺化合物
ES2527222T3 (es) Compuesto de azabiciclo y sal del mismo
AU2012303674B2 (en) Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
ES2494718T3 (es) Derivados de tetrahidro-pirido-pirimidina
CA2960275A1 (fr) Inhibiteurs de smyd
AU2017327539B2 (en) Heteroaryl carboxamide compounds as inhibitors of RIPK2
CA2904768A1 (fr) Inhibiteurs tricycliques d'ataxie-telangiectasie associee a rad-3 (atr)
US9150577B2 (en) Heterocyclic compounds containing an indole core
CA2932482A1 (fr) Imidazo[1,2-a]pyridine-3-carboxamides aryl et heteroaryl substitues et leur utilisation
TWI762534B (zh) 作為ＰＩ３Ｋδ抑制劑的咪唑並[1,5-A]吡衍生物
WO2019089835A1 (fr) Diazanaphthalèn-3-yl carboxamides, préparation et utilisation de ceux-ci
IL301767A (en) HSD17B13 inhibitors and uses thereof
JP2020502252A (ja) Ｄｙｒｋ１ａおよび／またはｄｙｒｋ１ｂキナーゼの阻害剤としてのキノリンの誘導体
EP3022193A1 (fr) Inhibiteurs de production de leucotriènes
CA3203922A1 (fr) Inhibiteurs enzymatiques
JP6522502B2 (ja) Ｗｎｔシグナル阻害剤
WO2023241322A1 (fr) Dérivés hétérocycliques, compositions et utilisations de ceux-ci
CA3097638A1 (fr) Composes amide en tant qu'inhibiteurs de la kinase, compositions et methodes de traitement
CN116981458A (zh) 具有四氢吲哚-1-甲酰胺作为bcl-2抑制剂的化合物
JPWO2006109867A1 (ja) ピラゾロ［１，５−ａ］ピリジン誘導体またはその医学上許容される塩

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10788192

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010788192

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012543150

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13513973

Country of ref document: US